































INTRODUCTION: Brain inflammation in 
metabolic syndrome  
 
Looking back upon the time when the human species 
had to spent tremendous efforts to gather enough food 
for survival, there is no doubt that modern 
industrialization has succeeded at making many choices 
of calorie-abundant food easily available with little 
physical efforts. However, this over-correction of food 
crisis has led to an opposite pattern of medical problems 
by introducing a worldwide outbreak of overnutrition-
related diseases such as obesity, type 2 diabetes (T2D), 
and cardiovascular diseases (CVDs) [1-7]. While this 
overnutrition-featured social economic environment 
will continue to exist, the health consequences are hefty 
and can threaten the fundamental welfare of modern 
humankind [8-12]. From the physiological perspective, 
outbursts of these health problems are often preceded by 
a cluster of interconnected pathophysiological 
abnormalities including obesity, insulin resistance, 
impaired  glucose   tolerance,   dyslipidemia  and   high  
 
 
































blood pressure, which are collectively called metabolic 
syndrome [13-19]. Thus, early therapeutic and 
preventive interventions against metabolic syndrome 
may represent an economic and effective strategy to 
control the deleterious outcomes of T2D and CVDs. 
However, there seems to be little progress in this aspect, 
largely due to insufficient understandings of the 
underlying root mechanisms of these disorders. 
However, cross-field studies from endocrinology and 
immunology have begun to change this landscape 
considerably since the last decade. A milestone 
discovery is that instead of merely being a contributor 
to energy excess, overnutrition has been recognized as 
an independent environmental factor that is targeted by 
innate immune system to trigger an atypical form of 
inflammation, which leads to metabolic dysfunctions at 
cellular, organ, and systemic levels [20-33]. 
Mechanistic studies further showed that such metabolic 
inflammation is related to the induction of various 
intracellular stresses such as mitochondrial oxidative 
stress, endoplasmic reticulum (ER) stress, and 
















cardiovascular  diseases,  has  reached  epidemic  levels  in  many  areas of  today’s  world.  Despite  this  alarming medicare
situation, scientific understandings on the root mechanisms of metabolic syndrome are still limited, and such insufficient
knowledge  contributes  to  the  relative  lack  of  effective  treatments  or  preventions  for  related  diseases.  Recent










www.impactaging.com                    98                                       AGING, February 2012, Vol.4 No.2autophagy defect under prolonged nutritional excess. 
More recently, this intracellular stress–inflammation 
process for metabolic syndrome has been established in 
the central nervous system (CNS) and particularly in the 
hypothalamus [28-46]. Importantly, the CNS and the 
comprised hypothalamus are known to govern various 
metabolic activities of the body including appetite 
control, energy expenditure, carbohydrate and lipid 
metabolism, and blood pressure homeostasis [47-63]. In 
the following sections, we describe recent research 
advances that address the roles of brain stress and 
inflammation in metabolic syndrome and related 
diseases from molecular, cellular, and physiological 
perspectives, with a particular emphasis on the 
comprised hypothalamus. 
 
Brain oxidative stress and metabolic syndrome 
 
Reactive oxygen species (ROS) refer to a class of 
radical or non-radical oxygen-containing molecules that 
have high oxidative reactivity with lipids, proteins, and 
nucleic acids. There are many potential sources of ROS 
in cells [64]. Mitochondria are the cellular organelles 
that generate energy in the form of ATP. However, this 
process is coupled with production and accumulation of 
oxidant by-products such as superoxide anions (O2-) 
within mitochondria and cytoplasm. Thus in quiescent 
cells, a large measure of intracellular ROS comes from 
the leakage of mitochondrial electron transport chain 
(ETC). Another major source of intracellular ROS is the 
intentional generation of superoxides by nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, 
which are used by cells for phagocytic defense or 
normal signaling. In addition, there are other ROS-
producing enzymes such as cyclooxygenases, 
lipoxygenases, xanthine oxidase, and cytochrome p450 
enzymes, which are involved with specific metabolic 
processes. To counteract the toxic effects of molecular 
oxidation by ROS, cells are equipped with a battery of 
antioxidant enzymes such as superoxide dismutases, 
catalase, peroxiredoxins, sulfiredoxin, and aldehyde 
dehydrogenases. When the production and clearance of 
ROS is balanced at a physiological homeostatic level, 
ROS does not pose a threat to cells. In fact, 
physiological levels of intracellular ROS can be 
normally involved in certain cell functions, such as 
membrane ion transport, generation of intracellular 
Ca2+ wave, activation of protein kinase, and regulation 
of gene expression [65]. However, when ROS 
homeostasis is disrupted due to various environmental 
or pathological factors, excessive ROS are accumulated 
in the mitochondria and cytoplasm – a condition 
referred to as intracellular oxidative stress, which can 
cause oxidative damages of cells and disease 
consequences [66-71]. Indeed, intracellular oxidative 
stress has been indicated to contribute to metabolic 
syndrome and related diseases, including T2D [72;73], 
CVDs [74-76], neurodegenerative diseases [69;77-80], 
and cancers [3;81]. 
 
The brain utilizes a large amount of oxygen and ATP to 
support its normal functions, resulting in a high 
susceptibility to oxidative stress [68;70;71;82]. Indeed, 
intracellular oxidative stress is highly associated with 
the development of neurodegenerative diseases [69] and 
brain aging [83], suggesting that CNS is an important 
site targeted by oxidative stress. This understanding 
brings up a question of whether brain oxidative stress 
could play an important role in the pathogenesis of 
metabolic diseases, given that the brain and particularly 
the hypothalamus are the central regulators of whole-
body energy and metabolic homeostasis. Despite that 
research exploration in this regard has been very 
limited, there is evidence in the literature supporting 
this hypothesis. For example, dietary obesity was found 
to induce NADPH oxidase-associated oxidative stress in 
rat brain [84], indicating that brain oxidative stress 
could potentially mediate the pathogenesis of 
overnutrition-related metabolic diseases. Other more 
direct evidences include that mitochondrial dysfunction 
in hypothalamic proopiomelanocortin (POMC) neurons 
causes central glucose sensing impairment [85], and 
brain mitochondrial dysfunction induced by genetic 
deletion of peroxisome proliferator-activated receptor 
coactivator 1α (PGC-1α) disrupts central regulation of 
energy homeostasis [86]. Thus, the role of brain 
oxidative stress in the development of metabolic 
diseases represents a new and highly interesting 
research topic. Overall, intracellular oxidative stress in 
the brain is potentially widely implicated in the 
pathogenesis of metabolic syndrome and related 
diseases, and defining the molecular and cellular 
pathways upstream and downstream of brain oxidative 
stress will significantly advance the mechanistic 
understandings of these diseases. 
 
Brain ER stress and metabolic syndrome 
 
Endoplasmic reticulum (ER) is the cellular organelle 
responsible for protein synthesis, maturation, and 
trafficking to secretory pathways. Since cellular 
metabolic demands undergo fluctuations depending on 
systemic physiological conditions, ER uses its unfolded 
protein response (UPR) machinery to fine tune its 
protein synthesis, folding, and secretion accordingly 
[87]. Three ER membrane-associated protein sensors, 
PKR-like endoplasmic reticulum kinase (PERK), 
inositol requiring enzyme-1 (IRE1), and activating 
transcription factor-6 (ATF6) act as protein sensors to 
initiate three branches of UPR pathways. When there is 
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are bound by chaperone protein BiP/GRP78 and stay in 
an inactive state. However, when there is an increase in 
the amount of newly synthesized protein or an 
accumulation of misfolded proteins in ER lumen, BiP is 
removed, resulting in activation of PERK and IRE1 and 
their downstream signaling cascades [87]. Activation of 
ATF6 additionally requires molecular reduction and 
translocation to Golgi [88;89]. Activated IRE1 produces 
an active form of transcription factor X-box binding 
protein-1 (XBP1), which together with ATF6 initiates 
transcription of genes that promote ER biogenesis, 
enhance ER folding capacity, promote secretion of ER-
associated proteins, and facilitate degradation of 
misfolded proteins [90;91]. The endoribonuclease 
activity of IRE1 also directly decreases protein 
translation by degrading mRNAs [92]. Activation of 
PERK leads to phosphorylation and activation of 
eukaryotic translational initiation factor 2α (eIF2α), 
which reduces global protein synthesis via competitive 
inhibition of eIF2B transcriptional complex [93]. 
Through a combination of these mechanisms, UPR can 
efficiently resolve ER stress and maintain ER 
homeostasis under physiological conditions. 
 
However, when cellular metabolic challenges that 
trigger ER stress is severe or persistent as in 
pathological settings, UPR may not be sufficient to 
neutralize ER stress, which leads to ER stress-related 
pathological changes at molecular, cellular, and 
systemic levels. Such unresolved ER stress can induce 
cell apoptosis [87;94], which forms the pathogenic basis 
for neurodegeneration, diabetic islet cell death, 
atherosclerosis, myocardial infarction, and stroke [95-
99]. Alternatively, ER stress can activate cellular 
inflammatory pathways which impairs cellular 
functions and leads to metabolic disorders [100]. In 
addition, ER stress causes cellular accumulation of ROS 
to induce oxidative stress [101], and oxidative stress 
reciprocally promotes ER stress by inhibiting ATF6 
activation [88], both of which synergistically contribute 
to the development of metabolic disorders. Indeed, ER 
stress has been associated to obesity, insulin resistance, 
T2D, CVDs, cancers, and neurodegenerative diseases 
[23;95;100;102;103]. Due to the central role of brain in 
metabolic control, the role of brain ER stress in 
metabolic disease has come into focus in recent years. 
Expanding the previous knowledge that brain ER stress 
underlies neurodegenerative diseases [95], recent 
studies have causally linked brain ER stress to the 
development of metabolic syndrome and related 
disorders such as overeating, obesity, leptin resistance, 
insulin resistance, β cell dysfunction, and hypertension 
[34;39;42;104;105] under conditions of overnutrition 
[34;42] and related inflammatory insults [105]. These 
findings have excitingly suggested brain ER stress as a 
novel therapeutic target for metabolic syndrome, and 
the underlying molecular basis of brain ER stress will 
be further discussed in the following relevant sections. 
 
Brain autophagy defect and metabolic syndrome 
 
Autophagy is an evolutionarily conserved lysosomal 
degradation pathway that plays essential roles in 
maintaining cellular homeostasis and promoting cell 
survival, growth, and differentiation against adverse 
conditions [106;107]. To maintain a healthy and 
functional intracellular environment, cells must 
constantly clean up defective proteins (e.g., misfolded 
proteins overflowing from ER stress) or damaged 
organelles (e.g., dysfunctional mitochondria from 
prolonged oxidative stress). This housekeeping function 
is carried out by three protein degradative machineries – 
ubiquitin-proteasome system (UPS), chaperone-
mediated autophagy (CMA), and macroautophagy 
(namely autophagy). UPS generally targets specific 
short-lived proteins, and CMA only degrades proteins 
containing particular peptide motifs. By comparison, 
only autophagy has the capacity for bulk degradation of 
long-lived cytosolic proteins and whole organelles. In 
the latter case, special terms such as mitophagy [108], 
reticulophagy [109], and pexophagy [110] were used to 
describe autophagy of dysfunctional mitochondria, ER, 
or excessive peroxisomes, respectively. Under normal 
growth conditions, autophagy occurs at a basal level to 
support cell growth, development and differentiation 
[111-117]. However, under environmental stress such as 
nutrient deprivation or hypoxia, autophagy is strongly 
induced to breakdown macromolecules into reusable 
amino acids and fatty acids for survival. From this 
perspective, complete loss of autophagy is lethal in 
experimental mice [114]. 
 
Tissue-specific impairment of autophagy, though not 
lethal, leads to the development of diverse diseases such 
as infection [118-120], cancer [121;122], muscle 
disorders [123], heart diseases [124], neurodegenerative 
diseases [115-117], and aging [125]. A common 
pathological feature of these diseases is the formation of 
intracellular aggregates from dysfunctional proteins or 
organelles [107]. The role of brain autophagy defect in 
metabolic syndrome has been nearly uninvestigated in 
the past. However, such prediction is well reasoned. 
First, studies of autophagy in specific peripheral tissues 
such as liver [126-129], skeletal muscle [130], and 
pancreatic β cells [131-133] have implicated autophagy 
defect in the pathogenesis of metabolic syndrome such 
as T2D and lipid disorders, with the only exception that 
autophagy defect in fat cells can impair adipogenesis to 
counteract fat expansion and the development of obesity 
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been causally linked to a number of neurodegenerative 
diseases including Alzheimer disease, Parkinson’s 
disease, Huntington’s disease, and transmissible 
spongiform encephalopathies [136-138], indicating an 

















































function. Indeed, we recently showed that intact 
autophagy function is required for the hypothalamus to 
properly control metabolic and energy homeostasis, 
while hypothalamic autophagy defect leads to the 
development of metabolic syndrome such as obesity 



























































dysfunctional  mitochondria,  ER,  and  other  cytosolic  proteins,  leading  to  increased  autophagy  stress  and
autophagic defect. All these intracellular stresses are activators of cellular proinflammatory kinases, among





cytokines  can  reinforce  metabolic  inflammation  via  cytokine  receptor  signaling.  Such  collective  onset  of
cellular  inflammation  impairs  normal  cellular  functions,  leading  to  central  dysregulation  of  various
physiological  processes  across  energy  balance,  glucose  tolerance,  and  cardiovascular  homeostasis,  which
underlies the development of metabolic syndrome and related diseases. 
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hypothalamic autophagy defect in metabolic syndrome? 
A plausible answer is brain autophagy defect may occur 
secondarily to oxidative stress and ER stress in the 
development of central metabolic dysregulations, 
presumably when intracellular accumulation of 
damaged mitochondria, ER, and misfolded proteins 
exceeds the degradative capacity of autophagy 
machinery. This hypothesis can be inferred from the 
observation that metabolic disorders related to central 
autophagy defect are late onset [40], and indeed 
prolonged oxidative stress or ER stress has been shown 
to impair autophagy function in disease milieu of cancer 
or aging [139;140]. But obviously further experimental 
investigations are needed to draw conclusions. 
 
Brain immune receptors and metabolic syndrome 
 
In addition to the primary roles of receptor-independent 
intracellular stress pathways in overnutrition-induced 
central metabolic dysregulations, immune receptor-
mediated pathways can also function in the 
hypothalamic inflammatory mechanisms of metabolic 
syndrome. In this regard, toll-like receptor (TLR) 
pathway has received substantial research attentions. 
TLRs are an important class of membrane-bound 
pattern recognition receptors in classical innate immune 
defense, primarily functioning to promote synthesis and 
secretion of immune response molecules upon binding 
by “non-self” molecules (e.g., pathogens) [141;142]. 
Most hypothalamic cell types including neurons and 
glia cells express TLRs and thus can mediate innate 
immune response to local or systemic inflammatory 
stimuli at least through TLRs [143-145]. In the context 
of metabolic dysregulations, overnutrition constitutes an 
environmental stimulus that can activate TLR pathways 
to mediate the development of metabolic syndrome 
related disorders such as obesity, insulin resistance, 
T2D, and atherosclerotic CVDs in rodents [146-157]. 
Isoforms TLR1, 2, 4, and 6 may be particularly 
pertinent to pathogenic signaling induced by lipid 
overnutrition, since these receptors are hyper-responsive 
to extracellular lipids as shown in studies on adipocytes, 
macrophages and myocytes [147-150]. The pathogenic 
significance of TLR signaling in metabolic syndrome 
has recently been appreciated in the CNS [36;37]. As 
shown in the literature, hypothalamic TLR4 and 
downstream inflammatory signaling are activated in 
response to central lipid excess via direct intra-brain 
lipid administration or HFD-feeding [36], while 
overnutrition-induced metabolic derangements such as 
central leptin resistance, systemic insulin resistance, and 
weight gain  can be significantly prevented in mice with 
brain-specific inhibition of TLR4 signaling [37]. 
Furthermore, brain-specific inhibition of TLR4 
signaling [37] reproduced the protective effects of 
whole-body TLR4 deficiency [36;154] against 
overnutrition. All these evidences based on brain TLR 
signaling further support the notion that CNS is the 
primary site for overnutrition to cause the development 
of metabolic syndrome. 
 
In addition to TLRs, cytokine receptors can also 
participate in the central induction of metabolic 
syndrome and related diseases, given that a prominent 
pathologic feature of these diseases, especially in the 
late stage, is the prevalent presence of cytokines in the 
circulation and various tissues of the body [20-30]. 
These circulating cytokines can limitedly travel to the 
hypothalamus through the leaky blood-brain barrier 
around the mediobasal hypothalamus to activate 
hypothalamic cytokine receptors. In addition to 
systemic cytokines, local inflammation in the brain 
induced by intracellular stresses can lead to local 
production and release of cytokines, which can work on 
cytokine receptors in adjacent neural cells. Through 
these combined actions, brain cytokine receptor 
signaling can help sustain and/or augment brain 
inflammation to underlie the escalation of metabolic 
disorders. 
 
Evidences supporting the involvement of cytokine 
receptors in central metabolic dysregulations mainly 
come from studies using central administration of 
cytokines or genetic deletions of cytokines or receptors. 
However, both approaches have pros and cons. The 
pharmacological studies, while having the advantage of 
directly targeting the brain, have major issues with dose 
usage. Most of the time, the doses applied did not 
reflect the pathophysiological levels in metabolic 
syndrome and related diseases, which unintentionally 
skewed the interpretations of their biological effects. 
The genetic knockout approach, while providing clean 
loss-of-function models to infer gene functions, has 
major limitations with site-specificity, i.e., most 
cytokine or cytokine receptor knockout models 
available now target the whole body instead of a 
specific tissue or cell type. Nonetheless, significant 
evidences have been recently documented 
demonstrating the role of cytokine receptor pathways in 
the development of metabolic syndrome components. 
For example, central administration of TNF-α at low 
doses faithfully replicated the effects of central 
metabolic inflammation in enhancing eating, decreasing 
energy expenditure [158;159], and causing obesity-
related hypertension [38]. Supportively, genetic 
deficiency of either TNF-α [160;161] or TNF-α receptor 
[158;162] prevented overnutrition from inducing 
obesity or insulin resistance in mice. Resistin, an 
adipocyte-derived proinflammatory cytokine, has been 
   
www.impactaging.com                    102                                      AGING, February 2012, Vol.4 No.2found to promote hepatic insulin resistance through its 
central actions [163]. On the contrary, anti-
inflammatory cytokines such as interleukin-10 or 
interleukin-6 were found to mediate the metabolic 
benefits of exercise through reducing hypothalamic 
inflammation [164]. Taken together, using specific 
forms, both TLR pathways and cytokine receptor 
pathways are involved in central inflammatory 
mechanism of metabolic syndrome and related diseases. 
Meanwhile, future studies are still needed to delineate 
the molecular signaling and potential neural cell type-
specificity of these programs. 
 
Brain oxidative stress and IKKβ/NF-κB signaling in 
metabolic syndrome 
 
Mammalian IκB kinase β (IKKβ) and nuclear factor-κB 
(NF-κB) comprise a master proinflammatory pathway 
that has pivotal roles in classical innate immune 
response [165]. In quiescent state, NF-κB resides in the 
cytoplasm in an inactive form due to inhibitory binding 
by IκBα protein. A wide range of extracellular immune 
stimuli can induce IKKβ activation via receptor-
mediated pathway, leading to IκBα phosphorylation and 
degradation and subsequent release of NF-κB activity. 
Activated NF-κB enters the nucleus to induce 
transcription of a myriad of genes that mediate diverse 
cellular processes such as immunity, inflammation, 
proliferation, apoptosis, and cellular senescence [166]. 
Research in the past decade has found that activation of 
IKKβ/NF-κB proinflammatory pathway in metabolic 
tissues is a prominent feature of various metabolic 
disorders related to overnutrition [20-33]. However, this 
type of inflammation has unique features compared to 
classical (e.g., pathogen-induced) inflammation. For 
instance, it happens in metabolic tissues, it is mainly 
associated with overnutrition-induced metabolic 
derangements, and most importantly, it is relatively 
low-grade and chronic. Hence, a special name of 
“metabolic inflammation” or “metaflammation” is 
given to refer to this type of atypical inflammation 
[28;29]. The biological effects of NF-κB-mediated 
metabolic inflammation are deleterious at cellular and 
tissue levels, including impairments of normal 
intracellular signaling and disruptions of metabolic 
physiology. More recently, this paradigm of IKKβ/NF-
κB-mediated metabolic inflammation has been 
identified in the CNS – particularly the comprised 
hypothalamus, which primarily accounts for to the 
development of overnutrition-induced metabolic 
syndrome and related disorders such as obesity, insulin 
resistance, T2D, and obesity-related hypertension [28-
46]. To understand the pathogenic signaling cascade 
mediated by IKKβ/NF-κB in the CNS, a keen research 
effort has been made to elucidate the intracellular 
changes that bridge overnutrition and hypothalamic NF-
κB activation. Albeit not fully developed, existing 
evidences have pointed to intracellular oxidative stress 
and mitochondrial dysfunction as upstream events that 
mediate hypothalamic NF-κB activation in a receptor-
independent manner under overnutrition. 
 
NF-κB is a redox-sensitive transcription factor whose 
activity is affected by cellular oxidative state [64;167]. 
A major mechanism that oxidative stress can activate 
NF-κB is through ROS-induced alternative 
phosphorylation of IκBα which abolishes its inhibition 
of NF-κB [168-172]. Additionally, oxidative stress can 
activate NF-κB pathway through oxidative inactivation 
of NF-κB pathway-related phosphatases such as IKK 
phosphatases and PTEN (phosphatase and tensin 
homolog, an Akt phosphatase), which causes 
upactivation of NF-κB pathway kinases such as IKKs 
(α, β, and γ) and Akt, leading to NF-κB activation [173-
175]. Activated NF-κB can induce cytotoxic products 
that exacerbate inflammation and oxidative stress and 
promote apoptosis [176], leading to oxidative stress-
induced cell dysfunction or cell death, respectively [64]. 
In the context of metabolic syndrome, oxidative stress-
related NF-κB activation in metabolic tissues or 
vascular systems has been implicated in a broad range 
of metabolic syndrome-related diseases, such as 
diabetes, atherosclerosis, cardiac infarct, stroke, cancer, 
and aging [177-184]. In the CNS, the potential link 
between oxidative stress and NF-κB-mediated 
inflammation in central metabolic dysregulations has 
not been adequately studied. However, such a 
mechanistic connection can be reasonably hypothesized 
based on several lines of evidence. First, overnutrition is 
an environmental inducer for intracellular oxidative 
stress regardless of tissues involved [7], because 
excessive nutrients, when transported into cells, directly 
increase mitochondrial oxidative workload, which 
causes increased production of ROS by mitochondrial 
ETC. Second, oxidative stress has been shown to 
activate NF-κB pathway in neurons or glial cells in 
several types of metabolic syndrome-related neural 
diseases, such as stroke [185], neurodegenerative 
diseases [186-188], and brain aging [189]. Third, central 
nutrient excess (e.g., glucose or lipids) has been shown 
to activate NF-κB in the hypothalamus [34-37] to 
account for overnutrition-induced central metabolic 
dysregulations. Additionally, mammalian histone 
deacetylase Sirtuin 1 has been shown to protect against 
metabolic syndrome related diseases such as 
atherosclerosis and aging, and such metabolic protective 
effects are associated with inhibition of ROS production 
and suppression of NF-κB activation [190;191]. Thus, 
intracellular oxidative stress seems to be a likely 
pathogenic link that bridges overnutrition with NF-κB 
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Finally, because activation of NF-κB pathway can 
reciprocally reinforce intracellular oxidative stress 
through induction of ROS-producing enzymes [176], 
the vicious cycle between oxidative stress and NF-κB 
activation may account for the refractory nature of 
overnutrition-induced metabolic disorders. Future 
studies of testing the pathogenic model of the 
connection between oxidative stress and NF-κB in the 
brain will help form a more complete understanding of 
the central mechanisms of overnutrition-induced 
metabolic diseases. 
 
Brain ER stress and IKKβ/NF-κB signaling in 
metabolic syndrome 
 
UPR signaling of ER can actively respond to changes of 
cellular nutrient state such as increased protein 
synthesis, glucose or energy deprivation, hypoxia, or 
even elevated intracellular lipid storage [87]. The 
underlying molecular events of UPR signaling include 
controlled transcription of many genes that are 
important for glucose and lipid metabolism [100]. In 
this context, ER is positioned to coordinate nutrient 
sensing with metabolism at the cellular level to 
safeguard systemic metabolic homeostasis. In support 
of this model, mice that are deficient in UPR pathways, 
such as PERK-deficient mice [192], eIF2α mutant mice 
[98;193] or mice with XBP1 haploinsufficiency 
deficiency [194], are prone to ER stress and develop 
metabolic disorders such as impaired glucose tolerance, 
insulin resistance, islet cell dysfunction, and increased 
adiposity. Along the same vein, overnutrition can 
present the cell with a metabolic overload that exceeds 
the physiological adaptive range of UPR, resulting in 
the development of ER stress and systemic metabolic 
disorders. Indeed, chronic ER stress in peripheral 
metabolic tissues such as adipocytes, liver, muscle, and 
pancreatic cells is a salient feature of overnutrition-
related diseases [100;194;195]. 
 
Further interests were diverted to how ER stress 
transduces overnutrition signals into metabolic 
derangements, and metabolic inflammation was brought 
upon as a mediator, as all three branches of UPR 
pathways are linked to proinflammatory IKKβ/NF-κB 
or JNK signaling [196-199]. However, it is difficult to 
mechanistically dissect the relationship between 
overnutrition, ER stress, and inflammation in peripheral 
tissues using animals that have already developed these 
abnormalities under chronic overnutrition, because 
obesity (the most common outcome of chronic 
overnutrition) and the associated systemic inflammation 
by themselves are potent inducers of ER stress. By 
contrast, this question has been well addressed in the 
CNS. Two recent studies showed that overnutrition 
induces ER stress as well as IKKβ/NF-κB activation in 
the hypothalamus of mice fed with a high-fat diet 
(HFD) [34], and central administration of ER stress 
inducer mimicked HFD feeding to activate 
hypothalamic NF-κB in mice on a normal chow diet 
[34;39]. More importantly, intra-third ventricle infusion 
of ER stress inhibitor suppressed the activation of 
hypothalamic NF-κB by HFD feeding [34], 
demonstrating that ER stress can act as a downstream 
effector of overnutrition to induce NF-κB-mediated 
inflammation in the brain. In the meanwhile, a sustained 
development of ER stress appears to depend on 
IKKβ/NF-κB pathway activity, because neither HFD 
feeding nor central administration of chemical ER stress 
inducer was able to induce hypothalamic ER stress in 
mice with central inhibition of IKKβ/NF-κB pathway 
[34;39]. Further bolstering the reinforcing effect of NF-
κB activation on ER stress, TNF-α, a product of NF-κB 
activation, was shown to induce ER stress in the 
hypothalamus, although the extent of stress induction by 
TNF-α itself was less than complete [105]. Finally, ER 
stress can indirectly promote inflammation via 
induction of oxidative stress [100;101]. Altogether, 
recent literature supports a model that brain ER stress 
and NF-κB activation reciprocally promote each other 
in the development of central metabolic dysregulations. 
Future studies may reveal more proinflammatory 
kinases associated with brain ER stress signaling under 
overnutrition, and different brain cell types may 
preferentially employ different signaling cascades in 
disease development. 
 
Brain autophagy defect and IKKβ/NF-κB signaling 
in metabolic syndrome 
 
As a stress-response mechanism against adverse growth 
conditions such as nutrient depletion, and as a 
machinery to maintain normal intracellular 
environment, autophagy is key to cell/organism survival 
and proper functioning [106;107]. Unsurprisingly, 
autophagy defect has been linked to the development of 
a number of systemic diseases [115-125] including 
metabolic syndrome, T2D, and lipid abnormalities [126-
133;200]. Of note, in the majority of these cases, the 
underlying pathogenesis lies in the failure of autophagy 
machinery to efficiently remove defective proteins or 
damaged organelles from the cytosol [107]. In terms of 
the pathogenic root of autophagy defect, chronic 
intracellular stress and particularly ER stress seem to be 
the critical upstream event. Indeed, ER stress has been 
shown to activate autophagy in mammalian cells 
through signaling crosstalk between autophagy and 
canonical UPR pathways [201;202]. Animal studies 
have shown that ER stress or oxidative stress induces 
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which helps restoring intracellular homeostasis by 
disposing a number of harmful molecules such as 
unfolded or misfolded proteins in ER lumen, cytosolic 
proteins damaged by ROS, or even dysfunctional ERs 
and mitochondria [203-205]. However, when 
intracellular stresses remain unresolved, prolonged 
autophagy upregulation progresses into autophagy 
defect [139;140]. Given that ER stress pathway is 
closely linked to proinflammatory pathways mediated 
by IKKβ/NF-κB [196-198] or JNK [199], it is logical to 
predict that autophagy changes are linked to these 
inflammatory pathways. In parallel, autophagy pathway 
can relate to proinflammatory signaling via oxidative 
stress pathway, as shown by a very recent report [206] 
that autophagic counteraction of intracellular oxidative 
stress can suppress cellular inflammation by inhibiting 
oxidative stress-induced NLRP3 inflammasome 
activation. Indeed, recent literature has shown that 
autophagy defect can induce NF-κB-mediated 
inflammation in association with the development of 
cancer or inflammatory diseases (e.g., Crohn’s disease) 
[207-211]. 
 
The connection between autophagy defect and 
proinflammatory activation of NF-κB pathway can also 
be inferred in metabolic syndrome, since both 
autophagy defect [126-133;200] and NF-κB activation 
[20-33] are implicated in the development of 
overnutrition-related metabolic diseases. This notion 
was recently experimentally proved in the CNS [40]. 
Mice with hypothalamic knockdown of autophagy-
related protein-7 (Atg7) developed hypothalamic 
autophagy defect and concomitant activation of 
hypothalamic IKKβ/NF-κB pathway. Moreover, 
hypothalamic autophagy defect can promote 
inflammatory activation to exacerbate the development 
of HFD-induced obesity and metabolic comorbidities 
[40]. The linear relationship from autophagy defect to 
NF-κB-mediated metabolic inflammation was 
demonstrated by the observation that hypothalamus-
specific IKKβ ablation abolished the deleterious effects 
of hypothalamic autophagy defect on central metabolic 
regulations [40]. 
 
Brain immune receptors and IKKβ/NF-κB signaling 
in metabolic syndrome 
 
Both TLR pathway and cytokine receptor pathways are 
closely related to IKKβ/NF-κB signaling in the central 
pathogenesis of metabolic syndrome. Overnutrition, 
especially in the form of HFD feeding, was shown to 
activate TLR4 signaling and downstream IKKβ/NF-κB 
pathway [36;37], leading to metabolic derangements 
such as central leptin resistance, systemic glucose 
intolerance, and weight gain [37]. In the study by 
Kleinridders et al [37], the critical involvement of TLR4 
signaling was demonstrated through brain-specific 
deletion of myeloid differentiation factor 88 (MyD88) – 
an essential signaling adaptor for TLR pathways to 
activate downstream proinflammatory signaling 
mediated by IKKβ/NF-κB or JNKs [212;213]. 
However, inhibition of central TLR4 signaling through 
brain-specific MyD88 deletion only abolished HFD-
induced IKKβ/NF-κB activation but not JNK activation 
in mouse hypothalamus [37], suggesting that 
differential upstream signaling mechanisms exist for 
different proinflammatory kinase pathways in central 
metabolic inflammation. Interestingly, Gorina et al 
[214] reported a similar signaling interplay in astrocyte 
inflammation, i.e., TLR4 activation leads to MyD88-
dependent NF-κB activation in early phase and MyD88-
indepdnent MAPK/JNK pathway in late phase. 
Together these studies point to NF-κB as an immediate 
signaling effector for TLR4 activation in central 
inflammatory response. In addition to directly activating 
proinflammatory kinase pathways upon overnutrition, 
TLR4 activation has been shown to induce intracellular 
ER stress to indirectly cause metabolic inflammation in 
the hypothalamus [36;105]. Thus, central TLR4–NF-κB 
pathway may represent one of the early receptor-
mediated events in overnutrition-induced central 
inflammation. 
 
The close link between IKKβ/NF-κB and cytokine 
receptor signaling in metabolic inflammation is beyond 
doubt, given that many cytokines and their receptors are 
both upstream activating components and downstream 
transcriptional targets of NF-κB activation [176]. For 
example, central administration of TNF-α at low dose 
can mimic the effect of obesity-related inflammatory 
milieu to activate IKKβ/NF-κB proinflammatory 
pathways, furthering the development of overeating, 
energy expenditure decrease, and weight gain [34;159]. 
However, the physiological effects of IKKβ/NF-κB 
activation seem to be cell type-dependent, i.e., 
IKKβ/NF-κB activation in hypothalamic agouti-related 
protein (AGRP) neurons primarily leads to the 
development of energy imbalance and obesity [34]; 
while in hypothalamic POMC neurons, it primarily 
results in the development of hypertension and glucose 
intolerance [38;39]. Thus, cautions should be taken 
when inferring the biological effects of cytokine 
receptor pathways in central metabolic inflammation. 
IKKβ/NF-κB activation has also been linked to cytokine 
receptor-mediated inflammatory signaling in non-
neuronal cells. For instance, central administration of 
interleukin-4 can induce microglial activation to 
promote the development of hypothalamic inflam-
mation and resulting weight gain, yet these effects are 
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[215]. Therefore, cytokine receptor signaling in glial 
cells may join neuronal inflammation, possibly via a 
paracrine mechanism, to cause the central dysregulation 
of metabolic physiology. The crosstalk between glial 
and neuronal cells in central metabolic inflammation 
still represents an under-investigated topic. 
 
Brain stress and therapeutic applications in obesity 
 
The CNS, particularly the hypothalamus, is the central 
regulator of energy and body weight balance [47-62]. 
This regulation critically depends on neurons that are 
located at different hypothalamic metabolic sensing 
centers, which through regulated release of 
neuropeptides and neurotransmitters [216-222], control 
downstream neuroendocrine and neural systems to 
affect feeding and energy expenditure. The ability to 
properly detect whole-body energy and nutrient states, 
i.e., metabolic sensing, is crucial for these first-order 
hypothalamic neurons to manage energy balance. At the 
molecular level, metabolic sensing of neurons is 
mediated critically by canonical leptin signaling via 
JAK2/STAT3 pathway and insulin signaling via 
PI3K/Akt pathway [47;53;58]. However, under 
pathological conditions such as overnutrition-induced 
intracellular metabolic stresses, neuronal 
proinflammatory pathways are activated, which in turn 
impairs leptin and insulin signaling, leading to neuronal 
dysfunction and central body weight dysregulation 
[223-230]. For example, HFD feeding-induced 
activation of IKKβ/NF-κB proinflammatory pathway in 
the hypothalamus [34-37;40], whether its upstream 
signaling event being ER stress [34;36], autophagy 
defect [40], or TLR activation [36;37], ultimately leads 
to increased energy intake, decreased energy 
expenditure, and the development of obesity. 
Accordingly, inhibition of hypothalamic IKKβ/NF-κB 
signaling effectively protects against these metabolic 
disorders, as shown by various experimental animal 
models including pharmacologic inhibition of 
hypothalamic IKKβ [35], brain-specific deletion of 
IKKβ [34], IKKβ/NF-κB signaling effector SOCS3 
[45;231] or TLR4 signaling adaptor MyD88 [37], or 
whole-body genetic deficiency of NF-κB subunit p50 
[232] or TLR4 [36;154]. In fact, the therapeutic effect 
of anti-inflammation against obesity condition has been 
demonstrated in human subjects as well. In a 
retrospective case-control study, anti-inflammatory 
intervention with aspirin was shown to significantly 
promote weight loss in patients with T2D [233]. Also, 
the appetite-suppressing and anti-weight gain effects of 
rimonabant are associated with systemic decrease of 
inflammatory response [234]. 
Brain stress and therapeutic applications in diabetes 
 
The hypothalamus plays a central role in controlling 
glucose homeostasis through coordinating the 
regulatory networks formed between multiple organs 
including brain, liver, pancreas, adipocytes, and skeletal 
muscles [55;235-239]. Specifically, metabolic signals 
such as circulating leptin, insulin, gut hormone, and 
nutrients act on certain hypothalamic neurons to inform 
the brain of whole-body glucose homeostatic state. 
These neurons in turn generate appropriate metabolic 
orders through downstream neuroendocrine and neural 
systems to control peripheral glucose metabolism [240]. 
In particular, AGRP neurons and POMC neurons of the 
arcuate nucleus in mediobasal hypothalamus and 
steroidogenic factor 1 (SF1) neurons in ventromedial 
hypothalamus have been recently identified to employ 
leptin and insulin signaling to regulate peripheral 
glucose homeostasis [241-244]. Resembling the central 
dysregulation of energy balance, overnutrition-induced 
intracellular stresses and the ensuing cellular 
inflammation impair the normal metabolic signaling in 
these glucose-regulating neurons [245-248], leading to 
central dysregulation of glucose homeostasis [249-251]. 
On the contrary, stress counteraction has been shown as 
an effective therapeutic strategy against overnutrition-
related glucose disorders in a battery of animal models. 
For example, ameliorating ER stress of obese mice 
through genetic overexpression of UPR components 
ATF6 [252], XBP1 [194], or ER chaperone proteins 
GRP78 [253], ORP150 [254], or pharmacologic 
administration of ER stress inhibitor 
tauroursodeoxycholic acid (TUDCA) [195], all 
improved glucose tolerance, insulin signaling, and 
related lipid disorders. More excitingly, this organelle-
specific therapy has proven effective for human T2D 
[255-257]. For example, TUDCA can improve liver and 
muscle insulin sensitivity by approximately 30% in 
obese men and women [258]. Stavudine, an antioxidant 
molecule that reduces ROS production and enhances 
mitochondrial function, can also increase muscle insulin 
sensitivity in humans [259]. Additionally, anti-
inflammation medications such as aspirin [260] and 
salsalate [261;262] have proven effective against T2D 
and related lipid disorders in clinical trials. Similarly, 
antagonizing systemic proinflammatory factors such as 
interleukin-1 [263] or TNF-α [264;265] also showed 
therapeutic effects against T2D. 
 
Brain stress and therapeutic applications in CVDs 
 
Many clinical and epidemiologic studies have 
demonstrated the therapeutic/preventive effects of anti-
cellular stress agents against CVDs. For example, 
dietary supplementation of antioxidant vitamin E can 
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increased production of oxidation-resistant low-density 
lipoprotein [266]. Antioxidant compounds that can 
reduce cellular oxidative stress and/or enhance 
mitochondrial respiratory function, such as coenzyme 
Q10, α-lipoic acid, and α-L-carnitine, have been shown 
to protect against myocardial dysfunction [267] or 
improve systolic blood pressure in patients with 
coronary artery disease [268]. Moreover, an increasing 
number of new cardiovascular drugs are being 
developed which belong to the same antioxidant 
category [269]. More recently, suppressing ER stress 
has been proposed as a potential treatment strategy 
against myocardial infarction and heart failure [99]. 
Brain stress, being a primary pathogenic basis of 
metabolic syndrome, conceivably can underlie the 
development of metabolic syndrome related CVDs. 
However, because the concept of brain stress in 
metabolic syndrome is a relatively recent establishment, 
there have not been many mechanistic studies which 
directly demonstrate their causal relationship or the 
therapeutic potentials of inhibiting brain stress in CVDs. 
Nonetheless, two very recent animal studies have 
pointed to this possibility [38;39]. Overnutrition-related 
metabolic inflammation in the hypothalamus, 
specifically in POMC neurons of the arcuate nucleus, 
was found to underlie the development of obesity-
related hypertension in mice [38]. Furthermore, POMC 
neuron-specific inhibition of this inflammatory pathway 
was shown to protect against the development of 
hypertension despite co-existing obesity or obesogenic 
condition [38]. In a following study [39] by the same 
group, brain ER stress was identified as the event 
upstream of hypothalamic NF-κB activation in the 
development of central inflammation-induced 
hypertension, and suppressing brain ER stress 
effectively prevented the development of overnutrition-
induced blood pressure disorders. 
 
CONCLUDING  REMARKS 
 
Research in the past decade has established that 
metabolic syndrome can result from innate immune 
activation in response to overnutrition. While this type 
of inflammation exists broadly across different tissues, 
the CNS is in a primary and wide-impact position for 
the induction of metabolic syndrome by nutritional 
inflammation. An inflammatory state in brain regulatory 
centers such as the hypothalamus disrupts its metabolic 
sensing function, which in turn affects downstream 
neural and neuroendocrine regulation of a wide range of 
physiological processes such as energy balance, glucose 
metabolism, and cardiovascular homeostasis. 
Dysregulations of these processes often happen 
concurrently and manifest as a cluster of highly 
associated metabolic disorders such as obesity, insulin 
resistance, and hypertension. Research in the past few 
years has significantly differentiated the hypothalamic 
inflammatory pathways underlying these metabolic 
disorders, and overnutrition-induced intracellular 
stresses have been recognized as key activators of 
metabolic inflammation in the hypothalamus. This new 
knowledge not only provides a conceptual framework 
for further dissecting the pathogenesis of metabolic 
syndrome related diseases, but also indicates potential 
interventional strategies of counteracting 
neuroinflammation against metabolic diseases. 
Regardless of this exciting status quo, many important 
questions still remain to be addressed experimentally. It 
is fair to say that current understandings on the central 
inflammatory mechanisms of metabolic syndrome and 
related diseases are still in a primitive stage. However, 
in light of its great significance from both biomedical 
research and therapeutic application perspectives, we 
expect major research endeavors being drawn to this 
field and more advances being made in the near future. 
We also anticipate that eventually these findings will be 
translated into novel and effective 
treatments/preventions against miscellaneous 
overnutrition-induced metabolic diseases. 
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